Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/considerations-regarding-antiretroviral-chemoprophylaxis-in-msm-JrybhECwmm
References (53)
-
A. Aghaizu, D. Mercey, A. Copas, M. Anne, Johnson, G. Hart, A. Nardone (2012)
Who would use PrEP? Predictors of use among MSM in London -
D. Krakower, M. Mimiaga, J. Rosenberger, D. Novak, J. Mitty, J. White, K. Mayer (2012)
Limited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking SitePLoS ONE, 7
-
Sheena McCormack, Sarah Fidler, Martin Fisher (2012)
The British HIV Association/British Association for Sexual Health and HIV Position Statement on pre-exposure prophylaxis in the UKInternational Journal of STD & AIDS, 23
-
M. Holt, D. Murphy, D. Callander, Jeanne Ellard, M. Rosengarten, S. Kippax, J. Wit (2012)
Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual menSexually Transmitted Infections, 88
-
R. Guy, A. McDonald, M. Bartlett, J. Murray, Carolien Giele, Therese Davey, Ranil Appuhamy, P. Knibbs, D. Coleman, M. Hellard, A. Grulich, J. Kaldor (2008)
Characteristics of HIV diagnoses in Australia, 1993-2006.Sexual health, 5 2
-
Jeffrey Martin, M. Roland, T. Neilands, M. Krone, J. Bamberger, R. Kohn, M. Chesney, Karena Franses, J. Kahn, T. Coates, M. Katz (2004)
Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behaviorAIDS, 18
-
H. Hall, R. Song, P. Rhodes, J. Prejean, Qian An, Lisa Lee, J. Karon, R. Brookmeyer, E. Kaplan, M. McKenna, R. Janssen (2008)
Estimation of HIV incidence in the United States.JAMA, 300 5
-
A. Liu, E. Vittinghoff, D. Sellmeyer, Risha Irvin, K. Mulligan, K. Mayer, M. Thompson, R. Grant, S. Pathak, B. O’Hara, R. Gvetadze, K. Chillag, L. Grohskopf, S. Buchbinder (2011)
Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San FranciscoPLoS ONE, 6
-
Lisa Eaton, S. Kalichman (2007)
Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologiesCurrent HIV/AIDS Reports, 4
-
G. Myers, K. Mayer (2011)
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.AIDS patient care and STDs, 25 2
-
M. Roland (2007)
Postexposure prophylaxis after sexual exposure to HIVCurrent Opinion in Infectious Diseases, 20
-
D. Krakower, K. Mayer (2011)
Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral MedicationsCurrent HIV/AIDS Reports, 8
-
M. Schechter, R. Lago, A. Mendelsohn, R. Moreira, L. Moulton, L. Harrison (2004)
Behavioral Impact, Acceptability, and HIV Incidence Among Homosexual Men With Access to Postexposure Chemoprophylaxis for HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 35
-
J. García-Lerma, R. Otten, S. Qari, E. Jackson, M. Cong, S. Masciotra, W. Luo, C. Kim, D. Adams, Michael Monsour, Jonathan Lipscomb, Jeffrey Johnson, D. Delinsky, R. Schinazi, R. Janssen, T. Folks, W. Heneine, A. Carr, St 's (2008)
Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent Prophylaxis with Emtricitabine and TenofovirPLoS Medicine, 5
-
J. García-Lerma, M. Cong, J. Mitchell, Ae Youngpairoj, Qi Zheng, S. Masciotra, Amy Martin, Z. Kuklenyik, A. Holder, Jonathan Lipscomb, C. Pau, J. Barr, D. Hanson, R. Otten, L. Paxton, T. Folks, W. Heneine (2010)
Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV InfectionScience Translational Medicine, 2
-
J. Kahn, Jeffrey Martin, M. Roland, J. Bamberger, M. Chesney, D. Chambers, Karena Franses, T. Coates, M. Katz (2001)
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.The Journal of infectious diseases, 183 5
-
J. Gallant, E. Dejesus, J. Arribas, A. Pozniak, B. Gazzard, R. Campo, B. Lu, D. Mccoll, S. Chuck, J. Enejosa, J. Toole, A. Cheng (2006)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.The New England journal of medicine, 354 3
-
O. Dosekun, J. Fox (2010)
An overview of the relative risks of different sexual behaviours on HIV transmissionCurrent Opinion in HIV and AIDS, 5
-
A. Fauci (2007)
Pathogenesis of HIV disease: opportunities for new prevention interventions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 45 Suppl 4
-
M. Roland (2006)
Enhancing the potential benefits of HIV post-exposure prophylaxis.AIDS, 20 14
-
R. Brooks, R. Landovitz, R. Kaplan, E. Lieber, Sung-Jae Lee, T. Barkley (2012)
Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study.AIDS patient care and STDs, 26 2
-
In response to the findings of the iPrEx trial, the CDC released interim guidance for healthcare providers in the USA for provision of PrEP to high-risk MSM -
A. Straten, J. Haberer (2012)
Unraveling the divergent results of PrEP Trials for HIV Prevention -
C. Tsai, K. Follis, A. Sabó, T. Beck, R. Grant, N. Bischofberger, R. Benveniste, R. Black (1995)
Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenineScience, 270
-
(2011)
& Centres for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men -
A. Grulich, J. Kaldor (2008)
Trends in HIV incidence in homosexual men in developed countries.Sexual health, 5 2
-
Rigmor Berg (2009)
The effectiveness of behavioural and psychosocial HIV/STI prevention interventions for MSM in Europe: A systematic review.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 14 48
-
M. Ardo, D. Ulver, C. Iesielski, P. Amela, R. Arcus, D. Biteboul, J. Eptonstall, F. Ot, P. Ibben, D. Ell (2009)
A Case–Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure, 12
-
C. Tsai, P. Emau, K. Follis, T. Beck, R. Benveniste, N. Bischofberger, J. Lifson, W. Morton (1998)
Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of TreatmentJournal of Virology, 72
-
(2002)
Recent ReferencesJournal of Human Lactation, 18
-
Charlene Flash, D. Krakower, K. Mayer (2012)
The Promise of Antiretrovirals for HIV PreventionCurrent Infectious Disease Reports, 14
-
M. Vourvahis, H. Tappouni, K. Patterson, Ya-Chi Chen, N. Rezk, S. Fiscus, B. Kearney, J. Rooney, J. Hui, M. Cohen, A. Kashuba (2008)
The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital TractJAIDS Journal of Acquired Immune Deficiency Syndromes, 47
-
(2012)
Intracellular tenofovir-DP concentra- tions associated with PrEP efficacy in MSM from iPrEx -
S. Golub, D. Operario, P. Gorbach (2010)
Pre-exposure Prophylaxis State of the Science: Empirical Analogies for Research and ImplementationCurrent HIV/AIDS Reports, 7
-
I. Zablotska, G. Prestage, A. Grulich, J. Imrie (2008)
Differing trends in sexual risk behaviours in three Australian states: New South Wales, Victoria and Queensland, 1998-2006.Sexual health, 5 2
-
R. Baggaley, R. White, M. Boily (2010)
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV preventionInternational Journal of Epidemiology, 39
-
F. Tissot, V. Erard, T. Dang, M. Cavassini (2010)
Nonoccupational HIV post‐exposure prophylaxis: a 10‐year retrospective analysisHIV Medicine, 11
-
S. Golub, William Kowalczyk, Corina Weinberger, J. Parsons (2010)
Preexposure Prophylaxis and Predicted Condom Use Among High-Risk Men Who Have Sex With MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 54
-
IPERGAY study press release: Launch of first pre-HIV exposure prevention trial for gay men in Europe -
K. Mayer, D. Krakower (2012)
Antiretroviral Medication and HIV Prevention: New Steps Forward and New QuestionsAnnals of Internal Medicine, 156
-
R. Otten, Dawn Smith, D. Adams, J. Pullium, E. Jackson, C. Kim, H. Jaffe, R. Janßen, S. Butera, T. Folks (2000)
Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2)Journal of Virology, 74
-
I. Poynten, F. Jin, L. Mao, G. Prestage, S. Kippax, J. Kaldor, J. Imrie, A. Grulich (2009)
Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual menAIDS, 23
-
L. Guay, P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, M. Deseyve, L. Emel, M. Mirochnick, M. Fowler, L. Mofenson, P. Miotti, Kevin Dransfield, D. Bray, F. Mmiro, J. Jackson (1999)
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 354
-
A. Straten, L. Damme, J. Haberer, D. Bangsberg (2012)
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV preventionAIDS, 26
-
K. Patterson, Heather Prince, E. Kraft, A. Jenkins, N. Shaheen, J. Rooney, M. Cohen, A. Kashuba (2011)
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 TransmissionScience Translational Medicine, 3
-
D. Ross (2010)
Behavioural interventions to reduce HIV risk: what works?AIDS, 24
-
T. Taha, N. Kumwenda, A. Gibbons, R. Broadhead, S. Fiscus, V. Lema, G. Liomba, Chiwawa Nkhoma, P. Miotti, D. Hoover (2003)
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trialThe Lancet, 362
-
T. Hawkins, Wenoah Veikley, R. Claire, Bill Guyer, Nicole Clark, B. Kearney (2005)
Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 39
-
E. Bernasconi, J. Jost, B. Ledergerber, B. Hirschel, P. Francioli, P. Sudre (2001)
Antiretroviral prophylaxis for community exposure to the human immunodeficiency virus in Switzerland, 1997-2000.Swiss medical weekly, 131 29-30
-
I. Poynten, D. Smith, D. Cooper, J. Kaldor, A. Grulich (2007)
The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIVHIV Medicine, 8
-
(2012)
Rilpavirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV-females and rectum in males -
R. Grant, J. Lama, P. Anderson, V. McMahan, A. Liu, Lorena Vargas, P. Goicochea, M. Casapia, J. Guanira-Carranza, María Ramírez-Cardich, Orlando Montoya-Herrera, T. Fernández, V. Veloso, S. Buchbinder, S. Chariyalertsak, M. Schechter, L. Bekker, K. Mayer, E. Kallás, K. Amico, K. Mulligan, Lane Bushman, Robert Hance, Carmela Ganoza, P. Defechereux, Brian Postle, Furong Wang, J. McConnell, Jia-Hua Zheng, Jean Lee, J. Rooney, H. Jaffe, Ana Martínez, D. Burns, D. Glidden (2010)
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.The New England journal of medicine, 363 27
-
Report of a WHO technical consultation. The strategic use of antiretrovirals for treatment and prevention of HIV infection
- Copyright
- Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
- ISSN
- 1746-630X
- eISSN
- 1746-6318
- DOI
- 10.1097/COH.0b013e3283582c71
- pmid
- 22918448
- Publisher site
- See Article on Publisher Site
Abstract
REVIEW URRENT Considerations regarding antiretroviral PINION chemoprophylaxis in MSM I. Mary Poynten, Iryna Zablotska, and Andrew E. Grulich Purpose of review HIV infection among MSM remains a significant issue. Data relevant to MSM populations from animal models, pharmacokinetic studies and clinical trials are summarized and challenges and potential consequences of use of preexposure prophylaxis (PrEP) by MSM are discussed. Recent findings Rectal simian–human immunodeficiency virus transmission in macaque models can be prevented by intermittent PrEP dosing. The Preexposure Prophylaxis Initiative (iPrEx) study found that daily oral emtricitabine-tenofovir disoproxyl fumarate (TDF/FTC) decreased HIV infection by 44% among 2499 high- risk MSM. Men with detectable levels of TDF or FTC in plasma and peripheral blood mononuclear cells experienced more than 90% protective effect, emphasizing the importance of adherence. In iPrEX and other studies, PrEP was generally safe and well tolerated. However, it appears that TDF use is associated with a small but significant decrease in mean bone mineral density. No risk compensation has been demonstrated, but this remains an area of potential concern when PrEP is used outside the setting of a placebo-controlled trial. Numerous PrEP trials in MSM are currently underway. Summary Oral FTC/TDF is effective in preventing HIV infection
Journal
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Nov 1, 2012